None listed
Conditions
Interventions
Intervention1: Curcumin: Oral Curcumin capsule 500 mg twice daily (morning , evening ) for 12 weeks
Control Intervention1: Placebo: Placebo Capsule oral twice daily morning evening for 12 weeks
Sponsors
Rohit Walia
Eligibility
Inclusion criteria
Inclusion criteria: People at risk of SARS-CoV 2 infection ( healthcare professionals , attendants of COVID patients , non COVID patients admitted in hospitals or his risk groups like elderly , cardiovascular patients , diabetes , obesity ) Not having a previous COVID19 diagnosis Not having experienced COVID19 symptoms since 30 th Jan 2020. Not having taken any pre-exposure prophylaxis ( HCQ , any other medication or Ayurvedic preparation or food supplement ) Having a negative SARS-CoV 2 test before randomisation
Exclusion criteria
Exclusion criteria: Any chronic infection Renal failure (CrCl Known history of hypersensitivity to the study drug or any of its components Immune suppressant drugs Recent vaccination within 2 month Pregnancy Primary Immunodeficiency states • Anemia Leukopenia Thrombocytopenia Co morbidities precluding survival required for duration of study follow up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. SARS-CoV 2 infection rate Using RTPCRTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of respiratory tract infections during course of study using the Wisconsin Upper Respiratory Symptom Survey Timepoint: 12 weeks;Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactRohit Walia
All India Institute of Medical Science Rishikesh
Outcome results
None listed